Zacks Investment Research upgraded shares of Scholar Rock (NASDAQ:SRRK) from a hold rating to a buy rating in a research report report published on Friday morning. They currently have $25.00 target price on the stock.

According to Zacks, “Scholar Rock Holding Corporation is a biopharmaceutical company. It focused on the discovery and development of medicines for treatment of serious diseases. The company’s product candidate includes SRK-015 and BMP6 which is in pre-clinical stage. Scholar Rock Holding Corporation is based in Cambridge, United States. “

A number of other brokerages have also commented on SRRK. Wedbush reiterated an outperform rating and set a $25.00 price target on shares of Scholar Rock in a report on Friday, November 9th. Cowen reiterated a buy rating on shares of Scholar Rock in a report on Monday, November 12th. Five analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and a consensus target price of $26.75.

SRRK opened at $20.06 on Friday. Scholar Rock has a twelve month low of $13.09 and a twelve month high of $27.02.

Hedge funds have recently modified their holdings of the company. TD Asset Management Inc. acquired a new position in shares of Scholar Rock during the second quarter worth approximately $183,000. Redmile Group LLC acquired a new position in shares of Scholar Rock during the second quarter worth approximately $27,306,000. Dean Capital Investments Management LLC acquired a new position in shares of Scholar Rock during the second quarter worth approximately $604,000. Millennium Management LLC acquired a new position in shares of Scholar Rock during the second quarter worth approximately $1,349,000. Finally, Quantitative Systematic Strategies LLC acquired a new position in shares of Scholar Rock during the second quarter worth approximately $193,000. Institutional investors own 51.03% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of various medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company is developing its lead antibody product candidate, SRK-015, a first-in-class inhibitor of the activation of myostatin that is in clinical development stage for the treatment of spinal muscular atrophy.

Featured Article: What are the components of an earnings report?

Get a free copy of the Zacks research report on Scholar Rock (SRRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.